Cisplatin

3:23
Improving the current chemotherapy standard: a role for DNA methyltransferase inhibitors
Simon Crabb
2:47
Current treatment landscape of triple negative breast cancer
Adrian Harris
3:08
KEYNOTE-048: pembrolizumab monotherapy for frontline R/M HNSCC
Barbara Burtness
3:28
Head and neck cancer challenges & cetuximab trial updates
Quynh-Thu Le
4:57
Cetuximab for oropharyngeal cancer: latest data from De-ESCALaTE
Hisham Mehanna
2:02
KEYNOTE-189: chemo plus pembrolizumab for NSCLC
Marina Garassino
2:38
The current treatment landscape for penile cancer
Lisa Pickering
2:34
Key trials that will affect the therapy landscape for NSCLC
Benjamin Besse
1:35
Cutting-edge UK trials for mesothelioma: double immuno, arginine depletion and molecular profiling
Dean Fennell
3:17
The development of immunotherapies in the treatment of relapsed metastatic head and neck cancer
Kevin Harrington
1:06
Head and neck cancers: an insight into the current studies
Athanassios Argiris
5:15
Results of ASCEND-4 trial of ceritinib versus chemotherapy in ALK+ NSCLC patients
Gilberto De Castro Jr
0:43
Double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in NSCLC
Rosalyn Juergens
The content of VJOncology is intended for healthcare professionals